As of Jun 23
| -0.40 / -0.84%|
The 12 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 58.50, with a high estimate of 87.00 and a low estimate of 36.00. The median estimate represents a +23.29% increase from the last price of 47.45.
The current consensus among 13 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.